Humacyte Financials

HUMA Stock

USD 0.94 0.05 5.62%

Based on the measurements of operating efficiency obtained from Humacyte's historical financial statements, Humacyte may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, Humacyte's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 141.2 M, whereas Short and Long Term Debt Total is forecasted to decline to about 18.1 M.

Covid

Interest Hikes

Humacyte Balance Sheet Chart

At present, Humacyte's Total Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 141.2 M, whereas Short and Long Term Debt Total is forecasted to decline to about 18.1 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Key indicators impacting Humacyte's financial strength include:

Current Value

Last Year

Change From Last Year

10 Year Trend

Current Ratio

2.62

2.76

Notably Down

Slightly volatile

The financial analysis of Humacyte is a critical element in measuring its lifeblood. Investors should carefully consider Humacyte's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(127.14 Million)

Build AI portfolio with Humacyte Stock

Understanding current and past Humacyte Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Humacyte's financial statements are interrelated, with each one affecting the others. For example, an increase in Humacyte's assets may result in an increase in income on the income statement.

Please note, the presentation of Humacyte's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Humacyte's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Humacyte's management manipulating its earnings.

Humacyte Stock Summary

Humacyte competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people.

Specialization	Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Instrument	USA Stock View All
Exchange	NASDAQ Exchange
ISIN	US44486Q1031
Business Address	2525 East North
Sector	Biotechnology
Industry	Health Care
Benchmark	Dow Jones Industrial
Website	humacyte.com
Phone	919 313 9633
Currency	USD - US Dollar

Humacyte Key Financial Ratios

	Return On Equity	-2.5
	Operating Margin	(32.39) %
	Price To Sales	115.27 X
	Gross Profit	(73.8 M)
	EBITDA	(132.23 M)

More Fundamentals

Humacyte Key Balance Sheet Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	286.5M	204.3M	128.2M	137.9M	124.1M	137.6M
Other Current Liab	6.8M	7.1M	9.4M	12.5M	14.4M	8.2M
Net Debt	(166.3M)	(99.7M)	(23.0M)	(28.4M)	(32.7M)	(34.3M)
Retained Earnings	(414.6M)	(426.5M)	(537.3M)	(686.0M)	(617.4M)	(648.3M)
Accounts Payable	2.1M	1.6M	6.5M	4.5M	5.2M	3.7M
Cash	217.5M	149.8M	80.4M	44.9M	40.4M	38.4M
Other Current Assets	3.7M	2.3M	2.8M	2.9M	3.4M	2.5M
Total Liab	164.4M	87.4M	114.7M	190.5M	219.1M	115.4M
Total Current Assets	229.3M	154.2M	83.3M	47.9M	43.1M	40.9M
Short Term Debt	2.0M	10.9M	2.6M	2.9M	3.4M	4.7M
Net Invested Capital	149.5M	145.8M	52.1M	(52.7M)	(60.6M)	(57.5M)
Net Working Capital	218.3M	134.6M	64.8M	27.9M	25.1M	23.9M

Humacyte Key Income Statement Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Interest Expense	4.3M	6.2M	6.6M	9.3M	10.7M	5.7M
Gross Profit	(60.1M)	(6.7M)	(76.6M)	(7.2M)	(8.3M)	(8.7M)
Operating Income	(81.2M)	(84.6M)	(100.0M)	(114.4M)	(103.0M)	(108.1M)
Ebit	(81.2M)	(84.6M)	(104.2M)	(139.4M)	(125.5M)	(131.8M)
Research Development	61.3M	63.3M	76.6M	88.6M	101.9M	76.9M
Ebitda	(73.0M)	(76.4M)	(96.5M)	(132.2M)	(119.0M)	(125.0M)
Cost Of Revenue	61.3M	8.3M	76.6M	7.2M	6.5M	6.1M
Income Before Tax	(26.5M)	(12.0M)	(110.8M)	(148.7M)	(133.8M)	(127.1M)
Net Income	(26.5M)	(12.0M)	(110.8M)	(148.7M)	(133.8M)	(127.1M)
Net Interest Income	(4.3M)	(3.6M)	(774K)	(5.2M)	(4.7M)	(4.9M)
Interest Income	16K	2.6M	5.7M	4.1M	4.7M	2.8M

Humacyte Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Humacyte's current stock value. Our valuation model uses many indicators to compare Humacyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Humacyte competition to find correlations between indicators driving Humacyte's intrinsic value. More Info.

Humacyte is rated # 5 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers . At present, Humacyte's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Humacyte's earnings, one of the primary drivers of an investment's value.

Most indicators from Humacyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.At present, Humacyte's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 538.6 M, whereas Selling General Administrative is forecasted to decline to about 22.2 M.

	2023	2024	2025	2026 (projected)
Interest Expense	6.6M	9.3M	10.7M	5.7M
Depreciation And Amortization	7.7M	7.2M	8.3M	8.5M

Interest Expense Depreciation And Amortization

Humacyte fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Other Liab
Total Assets		0.5	-0.28	-0.32	0.53	-0.1	0.23	-0.99	0.34	-0.56	0.96	-0.35	-0.41	0.97	0.2	-0.23	0.04	0.31	0.11	0.03	0.02	0.97	0.06	0.19	-0.02	0.53
Short Long Term Debt Total	0.5		-0.11	0.02	0.28	0.25	-0.06	-0.48	0.16	-0.07	0.69	-0.86	-0.26	0.69	-0.2	0.09	0.01	-0.11	0.28	0.23	0.01	0.69	0.25	-0.25	-0.3	0.39
Other Current Liab	-0.28	-0.11		0.93	-0.89	0.75	-0.94	0.3	-0.91	0.6	-0.32	0.36	0.91	-0.31	-0.79	0.94	0.93	-0.85	0.83	0.91	0.94	-0.29	0.06	-0.49	-0.86	0.48
Total Current Liabilities	-0.32	0.02	0.93		-0.83	0.77	-0.94	0.33	-0.87	0.5	-0.31	0.16	0.86	-0.3	-0.83	0.99	0.79	-0.96	0.77	0.9	0.81	-0.29	0.4	-0.54	-0.88	0.38
Total Stockholder Equity	0.53	0.28	-0.89	-0.83		-0.76	0.9	-0.55	0.97	-0.61	0.59	-0.31	-0.98	0.57	0.82	-0.81	-0.78	0.82	-0.73	-0.76	-0.8	0.56	-0.01	0.61	0.75	-0.39
Net Tangible Assets	-0.1	0.25	0.75	0.77	-0.76		-0.91	0.12	-0.83	0.2	-0.08	-0.18	0.75	-0.06	-0.99	0.78	0.79	-0.78	0.93	0.88	0.8	-0.04	0.34	-0.92	-0.93	0.71
Property Plant And Equipment Net	0.23	-0.06	-0.94	-0.94	0.9	-0.91		-0.25	0.96	-0.47	0.24	-0.08	-0.92	0.22	0.94	-0.95	-0.89	0.93	-0.92	-0.96	-0.91	0.21	-0.26	0.7	0.96	-0.61
Net Debt	-0.99	-0.48	0.3	0.33	-0.55	0.12	-0.25		-0.38	0.59	-0.96	0.32	0.43	-0.96	-0.22	0.24	-0.02	-0.33	-0.08	-0.01	0.0	-0.96	-0.09	-0.2	-0.01	-0.5
Retained Earnings	0.34	0.16	-0.91	-0.87	0.97	-0.83	0.96	-0.38		-0.53	0.41	-0.21	-0.98	0.39	0.87	-0.88	-0.85	0.88	-0.83	-0.87	-0.87	0.38	-0.11	0.63	0.86	-0.53
Accounts Payable	-0.56	-0.07	0.6	0.5	-0.61	0.2	-0.47	0.59	-0.53		-0.52	0.23	0.59	-0.52	-0.28	0.52	0.41	-0.5	0.3	0.39	0.42	-0.51	-0.43	-0.02	-0.34	-0.02
Cash	0.96	0.69	-0.32	-0.31	0.59	-0.08	0.24	-0.96	0.41	-0.52		-0.52	-0.49	1.0	0.17	-0.22	-0.03	0.29	0.09	0.02	-0.05	1.0	0.13	0.13	-0.03	0.47
Non Current Assets Total	-0.35	-0.86	0.36	0.16	-0.31	-0.18	-0.08	0.32	-0.21	0.23	-0.52		0.32	-0.52	0.14	0.13	0.27	0.03	-0.07	0.01	0.26	-0.52	-0.34	0.29	0.11	-0.24
Non Currrent Assets Other	-0.41	-0.26	0.91	0.86	-0.98	0.75	-0.92	0.43	-0.98	0.59	-0.49	0.32		-0.48	-0.8	0.86	0.82	-0.85	0.76	0.82	0.84	-0.46	0.06	-0.53	-0.79	0.46
Cash And Short Term Investments	0.97	0.69	-0.31	-0.3	0.57	-0.06	0.22	-0.96	0.39	-0.52	1.0	-0.52	-0.48		0.16	-0.21	-0.01	0.28	0.11	0.04	-0.03	1.0	0.13	0.12	-0.05	0.49
Net Receivables	0.2	-0.2	-0.79	-0.83	0.82	-0.99	0.94	-0.22	0.87	-0.28	0.17	0.14	-0.8	0.16		-0.83	-0.78	0.85	-0.91	-0.89	-0.8	0.14	-0.36	0.89	0.93	-0.64
Common Stock Shares Outstanding	-0.23	0.09	0.94	0.99	-0.81	0.78	-0.95	0.24	-0.88	0.52	-0.22	0.13	0.86	-0.21	-0.83		0.84	-0.96	0.82	0.94	0.86	-0.19	0.33	-0.52	-0.92	0.46
Non Current Liabilities Total	0.04	0.01	0.93	0.79	-0.78	0.79	-0.89	-0.02	-0.85	0.41	-0.03	0.27	0.82	-0.01	-0.78	0.84		-0.71	0.93	0.93	1.0	0.0	-0.02	-0.53	-0.89	0.75
Inventory	0.31	-0.11	-0.85	-0.96	0.82	-0.78	0.93	-0.33	0.88	-0.5	0.29	0.03	-0.85	0.28	0.85	-0.96	-0.71		-0.75	-0.87	-0.73	0.27	-0.44	0.56	0.88	-0.39
Other Current Assets	0.11	0.28	0.83	0.77	-0.73	0.93	-0.92	-0.08	-0.83	0.3	0.09	-0.07	0.76	0.11	-0.91	0.82	0.93	-0.75		0.96	0.93	0.13	0.15	-0.74	-0.96	0.85
Other Stockholder Equity	0.03	0.23	0.91	0.9	-0.76	0.88	-0.96	-0.01	-0.87	0.39	0.02	0.01	0.82	0.04	-0.89	0.94	0.93	-0.87	0.96		0.94	0.05	0.26	-0.62	-0.99	0.73
Total Liab	0.02	0.01	0.94	0.81	-0.8	0.8	-0.91	0.0	-0.87	0.42	-0.05	0.26	0.84	-0.03	-0.8	0.86	1.0	-0.73	0.93	0.94		-0.02	0.01	-0.54	-0.9	0.73
Total Current Assets	0.97	0.69	-0.29	-0.29	0.56	-0.04	0.21	-0.96	0.38	-0.51	1.0	-0.52	-0.46	1.0	0.14	-0.19	0.0	0.27	0.13	0.05	-0.02		0.13	0.1	-0.06	0.51
Short Term Debt	0.06	0.25	0.06	0.4	-0.01	0.34	-0.26	-0.09	-0.11	-0.43	0.13	-0.34	0.06	0.13	-0.36	0.33	-0.02	-0.44	0.15	0.26	0.01	0.13		-0.34	-0.33	0.04
Common Stock	0.19	-0.25	-0.49	-0.54	0.61	-0.92	0.7	-0.2	0.63	-0.02	0.13	0.29	-0.53	0.12	0.89	-0.52	-0.53	0.56	-0.74	-0.62	-0.54	0.1	-0.34		0.71	-0.55
Property Plant Equipment	-0.02	-0.3	-0.86	-0.88	0.75	-0.93	0.96	-0.01	0.86	-0.34	-0.03	0.11	-0.79	-0.05	0.93	-0.92	-0.89	0.88	-0.96	-0.99	-0.9	-0.06	-0.33	0.71		-0.74
Other Liab	0.53	0.39	0.48	0.38	-0.39	0.71	-0.61	-0.5	-0.53	-0.02	0.47	-0.24	0.46	0.49	-0.64	0.46	0.75	-0.39	0.85	0.73	0.73	0.51	0.04	-0.55	-0.74

Click cells to compare fundamentals

Humacyte Account Relationship Matchups

Humacyte fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	286.5M	204.3M	128.2M	137.9M	124.1M	137.6M
Other Current Liab	6.8M	7.1M	9.4M	12.5M	14.4M	8.2M
Net Debt	(166.3M)	(99.7M)	(23.0M)	(28.4M)	(32.7M)	(34.3M)
Retained Earnings	(414.6M)	(426.5M)	(537.3M)	(686.0M)	(617.4M)	(648.3M)
Accounts Payable	2.1M	1.6M	6.5M	4.5M	5.2M	3.7M
Cash	217.5M	149.8M	80.4M	44.9M	40.4M	38.4M
Other Current Assets	3.7M	2.3M	2.8M	2.9M	3.4M	2.5M
Total Liab	164.4M	87.4M	114.7M	190.5M	219.1M	115.4M
Total Current Assets	229.3M	154.2M	83.3M	47.9M	43.1M	40.9M
Short Term Debt	2.0M	10.9M	2.6M	2.9M	3.4M	4.7M
Net Invested Capital	149.5M	145.8M	52.1M	(52.7M)	(60.6M)	(57.5M)
Net Working Capital	218.3M	134.6M	64.8M	27.9M	25.1M	23.9M

Today, most investors in Humacyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Humacyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Humacyte growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.25)

At present, Humacyte's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Humacyte February 8, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Humacyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Humacyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of Humacyte based on widely used predictive technical indicators. In general, we focus on analyzing Humacyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Humacyte's daily price indicators and compare them against related drivers.

	Information Ratio	(0.16)
	Maximum Drawdown	21.58
	Value At Risk	(8.13)
	Potential Upside	8.16

Complementary Tools for Humacyte Stock analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Humacyte Financials

Humacyte Balance Sheet Chart

Net Income

(127.14 Million)

Humacyte Stock Summary

Humacyte Key Financial Ratios

Humacyte Key Balance Sheet Accounts

Humacyte Key Income Statement Accounts

Humacyte Financial Ratios Relationships

Humacyte fundamental ratios Correlations

Humacyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Humacyte fundamental ratios Accounts

Price Earnings To Growth Ratio

(0.25)

Humacyte February 8, 2026 Opportunity Range

Complementary Tools for Humacyte Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock Shares Outstanding	+ 0.99	Total Current Liabilities
Cash And Short Term Investments	+ 0.97	Total Assets

Property Plant Equipment	- 0.99	Other Stockholder Equity
Net Receivables	- 0.99	Net Tangible Assets
Net Debt	- 0.99	Total Assets
Non Currrent Assets Other	- 0.98	Retained Earnings
Non Currrent Assets Other	- 0.98	Total Stockholder Equity
Property Plant Equipment	- 0.96	Other Current Assets